Vita 34 AG
XETRA:V3V
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vita 34 AG
Net Income (Common)
Vita 34 AG
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vita 34 AG
XETRA:V3V
|
Net Income (Common)
€2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Net Income (Common)
€978.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Net Income (Common)
€1.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Net Income (Common)
HK$54.5m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Net Income (Common)
€978.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
Vita 34 AG
Glance View
Vita 34 AG engages in the collection and storage of umbilical cord blood and stem cells. The company is headquartered in Leipzig, Sachsen and currently employs 124 full-time employees. The company went IPO on 2007-03-27. The firm is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected at the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. They also allow the growing of whole organs, such as the liver. On average, one out seven individuals, whose cells are stored, receives autologous stem cell transplant by the age of 70. The firm acts as a cord blood bank and is also engaged in research activities in the area of regenerative medicine, including curing the consequences of strokes and heart attacks. The firm operates in Germany, Spain and Denmark.
See Also
What is Vita 34 AG's Net Income (Common)?
Net Income (Common)
2.6m
EUR
Based on the financial report for Sep 30, 2024, Vita 34 AG's Net Income (Common) amounts to 2.6m EUR.
What is Vita 34 AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
10%
